These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24976875)

  • 21. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action.
    Griffin MO; Ceballos G; Villarreal FJ
    Pharmacol Res; 2011 Feb; 63(2):102-7. PubMed ID: 20951211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells.
    Hanemaaijer R; Visser H; Koolwijk P; Sorsa T; Salo T; Golub LM; van Hinsbergh VW
    Adv Dent Res; 1998 Nov; 12(2):114-8. PubMed ID: 9972133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MMP-mediated events in diabetes.
    Ryan ME; Ramamurthy NS; Sorsa T; Golub LM
    Ann N Y Acad Sci; 1999 Jun; 878():311-34. PubMed ID: 10415738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of macrolides and tetracyclines for chronic inflammatory diseases.
    Voils SA; Evans ME; Lane MT; Schosser RH; Rapp RP
    Ann Pharmacother; 2005 Jan; 39(1):86-94. PubMed ID: 15562139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Host modulation therapy with anti-inflammatory agents.
    Preshaw PM
    Periodontol 2000; 2018 Feb; 76(1):131-149. PubMed ID: 29193331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines.
    Sorsa T; Tervahartiala T; Leppilahti J; Hernandez M; Gamonal J; Tuomainen AM; Lauhio A; Pussinen PJ; Mäntylä P
    Pharmacol Res; 2011 Feb; 63(2):108-13. PubMed ID: 20937384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of minocycline, platelet-derived growth factor, and transforming growth factor-beta on inflammatory repair potential in the periodontium.
    Soory M; Virdi H
    J Periodontol; 1999 Oct; 70(10):1136-43. PubMed ID: 10534066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives.
    Grenier D; Plamondon P; Sorsa T; Lee HM; McNamara T; Ramamurthy NS; Golub LM; Teronen O; Mayrand D
    J Periodontol; 2002 Jan; 73(1):79-85. PubMed ID: 11846203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood.
    Cazalis J; Tanabe S; Gagnon G; Sorsa T; Grenier D
    Inflammation; 2009 Apr; 32(2):130-7. PubMed ID: 19238528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetracyclines in the management of periodontal diseases. A review.
    Seymour RA; Heasman PA
    J Clin Periodontol; 1995 Jan; 22(1):22-35. PubMed ID: 7706536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.
    Lokeshwar BL
    Pharmacol Res; 2011 Feb; 63(2):146-50. PubMed ID: 21093590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases.
    Sorsa T; Ding Y; Salo T; Lauhio A; Teronen O; Ingman T; Ohtani H; Andoh N; Takeha S; Konttinen YT
    Ann N Y Acad Sci; 1994 Sep; 732():112-31. PubMed ID: 7978785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Doxycycline or how to create new with the old?].
    Shehwaro N; Langlois AL; Gueutin V; Gauthier M; Casenave M; Izzedine H
    Therapie; 2014; 69(2):129-41. PubMed ID: 24926631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms.
    Golub LM; Lee HM; Ryan ME; Giannobile WV; Payne J; Sorsa T
    Adv Dent Res; 1998 Nov; 12(2):12-26. PubMed ID: 9972117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemically modified tetracyclines: The novel host modulating agents.
    Swamy DN; Sanivarapu S; Moogla S; Kapalavai V
    J Indian Soc Periodontol; 2015; 19(4):370-4. PubMed ID: 26392682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution.
    Garrido-Mesa J; Rodríguez-Nogales A; Algieri F; Vezza T; Hidalgo-Garcia L; Garrido-Barros M; Utrilla MP; Garcia F; Chueca N; Rodriguez-Cabezas ME; Garrido-Mesa N; Gálvez J
    Br J Pharmacol; 2018 Dec; 175(23):4353-4370. PubMed ID: 30184260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
    Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
    Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.
    Holmes SG; Still K; Buttle DJ; Bishop NJ; Grabowski PS
    Bone; 2004 Aug; 35(2):471-8. PubMed ID: 15268899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Nonantimicrobial effects of tetracyclines].
    García-Alvarez L; Oteo JA
    Rev Esp Quimioter; 2010 Mar; 23(1):4-11. PubMed ID: 20232018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.